3 / 27
response for pembrolizumab
monotherapy in advanced solid
tumors
Percentage of metastatic tumors
with PD-L1>75% quartile
(95% confidence interval)
Limited clinical activity of PD-1 antibodies
Established clinical activity of PD-1 antibodies
Indications outlined in keynote-012 trial
Pursued through collaboration with JHU
80%
70%
60%
50%
40%
30%
20%
10%
0%
Breast_luminal A (52)
Pancreas_adenocarcinoma (46)
Breast_luminal B (235)
Uterus/endometrium (86)
Colorectal (775)
Breast_HER2
+
(28)
Gastric (20)
Bladder (94)
Kidney_clear cell (59)
Breast_TN (161)
Head-neck (140)
Lung squamous (43)
Melanoma (565)
Colorectal-MSI (27)
Lung_adenocarcinoma (197)
Prostate (28)
Liver (14)
Ovary_serous (218)
Tier 1
Tier 2
Tier 3
Breast_luminal A (1356)
Prostate (258)
Pancreas_adenocarcinoma (305)
Brain_giloblastoma (227)
Breast_luminal B (1220)
Uterus/endometrium (717)
Colorectal (1399)
Breast_HER2
+
(195)
Gastric (115)
Bladder (326)
Kidney_clear cell (583)
Breast_TN (735)
Head-neck (122)
Lung squamous (612)
Melanoma (159)
Colorectal-MSI (172)
Lung_adenocarcinoma (1237)
Liver (104)
Ovary_serous (248)
10%
0%
B
Ayers, M et al. Clin Cancer Res 2018